Halozyme Names Darren Snellgrove Chief Financial Officer to Lead Financial Strategy and Capital Allocation
Darren Snellgrove Halozyme Therapeutics, Inc. (Nasdaq: HALO) has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, as the biopharmaceutical company looks to...
